

## **Notice on Decision by the UK Competition and Markets Authority Concerning Medreich PLC**

Medreich Limited announces that, on 3 February 2022 (UK time), its subsidiary Medreich PLC received a Decision Notice from the Competition and Markets Authority (CMA) of the United Kingdom ordering payment of a fine in the amount of GBP 4,620,000 for violation of the UK Competition Act 1998.

This Decision follows an investigation by the CMA into the possibility that certain conduct related to a generic pharmaceutical, Prochlorperazine 3mg buccal tablets, in the UK restricted competition. The CMA determined the relevant conduct related to period from February 2014.

In October 2017, Medreich PLC received notice from the CMA indicating that it had grounds for suspecting that the company had engaged in conduct that infringed competition law and the company has since fully cooperated with the investigation. Medreich PLC has also worked to strengthen governance through measures that include training related to reoccurrence prevention and the reevaluation of contracts.

As soon as Medreich Limited became aware of this investigation, it instructed Medreich PLC to cease any relevant conduct, ordered full cooperation with the investigation, and has since reinforced measures to prevent reoccurrence.

We, Medreich Group, take the details of this Decision seriously, and are committed to ensuring all our affiliates implement reoccurrence prevention measures and reinforce compliance with all relevant laws and regulations.

Contact to:

Medreich PLC

Ashish Gupta, CFO

Telephone: +44(0)20 8831 1500